Hence, therapeutic application of our findings for treatment of autoimmune disease may require additional targets for the depletion of plasma cells, but, given the comparably high level of plasma cell specificity, FKBP11-directed drugs could be used to specifically target the ER-resident folding machinery in plasma cells. This evidence concerns the gene FKBP11 and autoimmune disease.